Currently, intensive efforts have been made to restore wildtype p53 activity as an anticancer therapeutic pathway [31].iASPP, as the inhibitor of p53, have arouse enough attentions in the therapeutic target of acute leukemia. Here, PPP1R13L is linked to acute leukemia.